Ferozsons Laboratories Limited ki subsidiary BF Biosciences Limited ne Human insulin “Ferulin” ka kamyab tareen launch kar diya hai.
Is launch se diabetes ko roknay mein madad denay, or ferozsons kay product portfolio ko barhanay aur market mein zindagi bachanay wali dawayon ki farahmi ko mazeed behtar bananay ka aham qadam darj kiya hai.
Ferulin ko higher standards ke sath tayyar kiya gaya hai aur is ka maqsad Pakistan bhar mein mareezon ko mustasna aur maqbul qeemat par diabetes ka ilaaj faraham karna hai.
BF Biosciences Limited (BFBL) ne Pakistan Stock Exchange (PSX) ke main board par listing ke liye darkhwast de di hai. BFBL ka irada hai ke woh 25 million shares institutional, high net worth, aur individual investors ko farokht karke kam az kam PKR 1.37 billion ikattha kare. Ye sab regulatory approval milne par mabni hai.
Pakistan ka pehla biotech plant hone ki sifat se BF Biosciences Limited ne das saal se zyada arsay se HCV, Cancer, Cardiology aur dusre ilmi ilaqon ke ilaj ke liye zaroori dawayon ki tajveez ki hai. Company yaqeen rakhty hai ke Ferulin subsidiary ke izafay mein musbat asar andaz hoga aur companyi maqsad mein izafa karega ke ghair mukammal mareez ki zarooriyat ko pura kare.
